CurveBeam Al Limited's Update on Enhanced HiRiseTM Validation

CurveBeam Al Limited (ASX:CVB) has provided an update on the validation of the enhanced HiRiseTM for a key robotic surgical system. Following the recent FDA clearance, the Company has completed key validation steps for robotic surgical systems at two US based sites with the enhanced HiRiseTM, achieving image quality generally at par with conventional CT scans. The vendor has advised a pause in further imaging while determining next steps to finalize the validation process.

Executive Commentary on Enhanced HiRiseTM Validation

To be able to generate images at par with conventional CT on the enhanced HiRise is a fantastic outcome and I congratulate our R&D team on delivering this. We will update the market on the expected timeline to complete the validation following further instruction from the vendor.

Summary of CurveBeam Al's Enhanced HiRiseTM Validation Update

CurveBeam Al Limited (ASX:CVB) has successfully completed key validation steps for the enhanced HiRiseTM for robotic surgical systems, achieving image quality generally at par with conventional CT scans. The Company will update the market on the expected timeline to complete the validation following further instruction from the vendor. CurveBeam Al's flagship CT scanner, HiRiseTM, offers weight bearing CT scans as well as traditional non-weight bearing CT scans, providing a range of advantages over traditional CT or MRI devices. The Company's global operations headquarters are in Hatfield, Pennsylvania, USA, and it has corporate offices, Al, and IP functions located in Melbourne, VIC, Australia.